Strategic asset sales RedHill has actively divested non-core assets (Talicia to Apotex; other asset sales) to fuel strategic growth, creating potential openings for partners or new licensing opportunities in complementary GI and infectious disease portfolios.

Global rights expansion Recent licensing and acquisition activity secures exclusive global commercialization rights for certain assets (Rebyota, Clenpiq) and worldwide development rights for RHB-102 outside North America, signaling opportunities for channel expansion, co-promotion, and regional partnerships.

Pediatric and rare disease focus FDA rare pediatric disease designation for opaganib in neuroblastoma highlights a patient-segment focus that may align with partnerships in rare pediatric oncology, potential grant funding, and specialized manufacturing or supply arrangements.

Pipeline and tech leverage A diversified pipeline combined with multiple technology platforms offers risk-balanced expansion chances; potential sales opportunities exist in cross-promoting pipeline candidates to GI and infectious disease specialists and negotiating milestone-driven deals with risk-sharing components.

Market readiness and partnerships Recent collaborations (Cumberland for Talicia, licensing with Hyloris for RHB-102) indicate a pattern of strategic partnerships to accelerate market access; explore co-development, distribution, or regional co-promotion deals to capitalize on established go-to-market channels.